MDACC Study No:2009-0717 ( NCT No: NCT01094860)
Title:A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients with Relapsed / Refractory Lymphoid Malignancies.
Principal Investigator:Tapan Kadia
Treatment Agent:Nelarabine
Study Status:Open
Study Description:The goal of the clinical research study is to find the highest tolerable dose
of nelarabine when given as a continuous infusion to patients with a lymphoid
malignancy that has not responded to, or has come back after treatment with
chemotherapy. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Nelarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:If hospitalized, length of hospitalization would be 5 days every 28 days.
Supported By:GlaxoSmithKline
Return Visit:Weekly
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Tapan Kadia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults